# Rindopepimut

Source: https://onco.cc/drugs/rindopepimut/  
OnCo record `rindopepimut` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rindopepimut is a peptide vaccine against EGFRvIII, a mutant protein found only on some glioblastomas. After a phase 2 that beat historical controls, the 745-patient double-blind phase 3 ACT IV found no benefit in 2016, and tumours in both arms had lost EGFRvIII at recurrence, a lesson in antigen escape.

## Summary

EGFRvIII peptide conjugated to KLH with GM-CSF. Phase 2 (ACT III) suggested prolonged survival versus historical controls; the double-blind phase 3 ACT IV (n=745, EGFRvIII-positive newly diagnosed glioblastoma with minimal residual disease) showed no OS benefit (20.1 vs 20.0 months). Loss of EGFRvIII expression at recurrence in both arms illustrated antigen escape. Celldex discontinued the programme.

## Fields

- Kind: Treatment
- Status: negative
- Last checked: 2026-09-06
- Code: CDX-110
- Modality: Peptide vaccine (EGFRvIII)
- Mechanism: Induces humoral and cellular immunity against the EGFRvIII neoepitope.

## Sources

- ClinicalTrials.gov NCT01480479 (ACT IV): https://clinicaltrials.gov/study/NCT01480479

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [Celldex Therapeutics](https://onco.cc/companies/celldex/)
- terms: [EGFRvIII](https://onco.cc/terms/egfrviii/)
- trials: [ACT IV](https://onco.cc/trials/act-iv/)
- bottlenecks: [The brain: barrier and sanctuary](https://onco.cc/bottlenecks/b-brain-delivery/)

---
JSON: https://onco.cc/api/v1/entities/rindopepimut.json